Ibogaine Drug Interactions & Medication Safety

Drug classes never combined with ibogaine: SSRIs/SNRIs, methadone, MAOIs, tramadol, QT-prolonging drugs, and high-dose benzodiazepines.

Required washout periods range from 14 days (buprenorphine minimum) to 6 weeks (fluoxetine), depending on half-life and mechanism.

The liver enzyme that converts ibogaine to noribogaine. Inhibitors raise ibogaine levels; inducers lower them — both are clinically significant.

Reputable clinics require ECG, metabolic panel, electrolytes, CBC, urine tox, and a full pharmacological medication review before treatment.

Ibogaine and its metabolite noribogaine are potent serotonin reuptake inhibitors. Combining them with SSRIs (fluoxetine, sertraline, escitalopram, paroxetine, citalopram, fluvoxamine) or SNRIs (venlafaxine, duloxetine, desvenlafaxine) creates additive serotonergic overload, causing serotonin syndrome — a potentially fatal condition characterized by hyperthermia, muscle rigidity, clonus, and autonomic instability. Fluoxetine is particularly dangerous due to its 4-6 week half-life; residual drug remains active long after the last dose.

Methadone alone is one of the most potent QT-prolonging medications in clinical use. Combining it with ibogaine — which independently prolongs the QT interval by blocking hERG potassium channels — creates a dangerous synergistic effect that dramatically increases Torsades de Pointes (TdP) risk. Multiple ibogaine-related fatalities have specifically involved concurrent methadone use. Additionally, methadone has an extremely long and unpredictable half-life (24-60 hours, sometimes up to 120 hours in slow metabolizers), meaning patients cannot simply stop the day before treatment. A structured methadone-to-buprenorphine bridge under medical supervision, followed by a buprenorphine taper, is the standard protocol — a process that typically takes 4-8 weeks minimum.

MAOIs (phenelzine, tranylcypromine, isocarboxazid) irreversibly inhibit monoamine oxidase, preventing the breakdown of serotonin, dopamine, and norepinephrine. Ibogaine, which drives serotonin release and blocks reuptake, combined with an MAOI creates a catastrophic excess of synaptic serotonin — a serotonin crisis. Even reversible MAOIs (moclobemide) and certain antibiotics or antivirals with MAOI activity (linezolid, methylene blue) are contraindicated. The washout period for irreversible MAOIs is a minimum of 14 days; for moclobemide, 48 hours.

Tramadol has a dual mechanism: it is a weak opioid agonist and a serotonin-norepinephrine reuptake inhibitor. Both mechanisms are problematic with ibogaine. The serotonin reuptake inhibition creates additive serotonergic risk, while tramadol independently lowers the seizure threshold. Ibogaine also lowers the seizure threshold. The combination significantly elevates seizure risk beyond either drug alone. Additionally, tramadol is metabolized by CYP2D6 — the same enzyme that metabolizes ibogaine — creating metabolic competition and producing unpredictable plasma levels of both compounds.

Any medication that prolongs the QTc interval through hERG potassium channel blockade is contraindicated with ibogaine. This includes: antiarrhythmics (amiodarone, sotalol, quinidine, flecainide, dronedarone); antipsychotics (haloperidol, ziprasidone, quetiapine, risperidone — note that olanzapine and clozapine also carry risk); certain antibiotics (azithromycin — the most commonly prescribed QT offender — clarithromycin, fluoroquinolones including ciprofloxacin, levofloxacin, and moxifloxacin); antifungals (fluconazole, ketoconazole); and antihistamines (astemizole, terfenadine). The authoritative resource for the full QT drug risk list is CredibleMeds (crediblemeds.org) and the Arizona CERT database.

Benzodiazepines (diazepam, alprazolam, clonazepam, lorazepam, temazepam) create risks with ibogaine from two opposing directions. High-dose or recent acute use risks respiratory depression from combined CNS depressant effects. More critically, abrupt benzodiazepine cessation in a dependent patient triggers withdrawal-related seizures — and ibogaine independently lowers the seizure threshold, compounding the risk severely. Patients on chronic benzodiazepines must complete a gradual physician-supervised taper over 4-12 weeks before ibogaine treatment. This is not optional.

Buprenorphine has exceptionally high mu-opioid receptor affinity. It occupies and blocks opioid receptors, preventing ibogaine from engaging them — which dramatically blunts ibogaine's anti-addictive mechanism and effectiveness. The minimum washout after the last dose is 7-14 days, though most clinics require patients to taper to 2mg or less before discontinuing. The lower the final dose, the shorter the washout required. A slow taper from therapeutic doses (8-24mg) typically takes 4-8 weeks, with the final 2mg-to-zero transition being the hardest step. Precipitated withdrawal — which ibogaine cannot reverse due to buprenorphine's receptor blockade — is the clinical danger if washout is insufficient.

Fluoxetine has the longest half-life of all SSRIs (1-6 days for fluoxetine, 4-16 days for norfluoxetine). Meaningful plasma levels persist for 4-6 weeks after the final dose. Most clinical pharmacology consultants require plasma-level confirmation that both fluoxetine and norfluoxetine are below detection threshold before ibogaine treatment proceeds. The taper itself should be gradual to minimize discontinuation syndrome; even with its long half-life providing natural tapering, dose reductions should be planned over 4-8 weeks from therapeutic doses.

These SSRIs have half-lives of 24-36 hours and are substantially cleared within 2-3 weeks of the final dose. However, the taper itself may take 4-8 weeks depending on dose — abrupt discontinuation of sertraline above 50mg causes pronounced discontinuation syndrome in most patients (dizziness, brain zaps, irritability, flu-like symptoms). A standard approach is dose reduction by 25-50mg every 2-4 weeks. Citalopram carries an additional concern: it independently prolongs the QT interval at higher doses (above 40mg), making baseline ECG review particularly important for patients with citalopram history.

Paroxetine has the most severe discontinuation syndrome of all SSRIs. It is also a potent CYP2D6 inhibitor — the enzyme primarily responsible for ibogaine metabolism — which could raise ibogaine plasma levels if any residual inhibition persists. Tapering paroxetine requires significant patience: dose reductions of 10mg every 2-4 weeks are typical, and some patients require liquid formulation for precision micro-tapering. The total taper timeline from 40-60mg commonly reaches 3-4 months. Plan ibogaine treatment timelines accordingly.

The taper timeline depends entirely on dose, duration of use, and specific benzodiazepine. Shorter-acting benzodiazepines (alprazolam, lorazepam) often benefit from a 'Valium switch' — conversion to an equivalent dose of diazepam (long-acting), followed by a slow diazepam taper at approximately 2-5mg per week using the Ashton protocol. Patients who have been on benzodiazepines for years may require multi-month tapers. The ibogaine clinic should receive documentation of the completed taper and a clearance ECG. Some clinics will not accept patients who have used benzodiazepines in the prior 30 days regardless of dose.

Venlafaxine has one of the most difficult discontinuation syndromes in psychiatry, with even one missed dose causing brain zaps, dizziness, and emotional disturbance. Duloxetine has a somewhat smoother discontinuation profile. Both drugs inhibit serotonin and norepinephrine reuptake — creating dual-pathway serotonergic risk with ibogaine. Venlafaxine should be tapered by 37.5mg per 2-4 weeks, and the final transition from 37.5mg to zero often requires use of liquid formulation or bead-counting from capsules. Many clinicians bridge to fluoxetine for the final taper steps due to fluoxetine's self-tapering nature from its long half-life.

Generally compatible after cardiovascular screening. Blood pressure should be well-controlled before ibogaine. Beta-blockers require ECG review as they affect heart rate during monitoring. Metoprolol and atenolol are typically fine at standard doses. Diuretics require electrolyte monitoring — they can cause hypokalemia that worsens QTc prolongation.

Thyroid hormone replacement is generally compatible with ibogaine. Thyroid levels should be optimized and stable before treatment. Hyperthyroidism — including iatrogenic over-replacement — increases cardiac sensitivity and should be controlled prior to dosing. Ensure TSH is within normal range at the pre-treatment screen.

PPIs have no known clinically significant interaction with ibogaine. They are often continued through the treatment period. Note that CYP2C19 polymorphisms affect PPI metabolism and may occasionally affect ibogaine pharmacokinetics indirectly.

Magnesium supplementation is actively beneficial: it reduces ibogaine-induced tremors and provides electrolyte support for cardiac function. Magnesium taurate or glycinate is preferred. High-dose B6 (pyridoxine) above 100mg/day warrants discussion — it can affect serotonin synthesis at very high doses but is generally fine at standard supplementation levels.

Acetaminophen is acceptable at standard doses, though patients should minimize use given ibogaine's hepatic metabolism. NSAIDs are generally fine but should be used cautiously with any liver function concerns or GI issues. Aspirin (low-dose, 81mg) is typically continued in patients taking it for cardiac indications.

Anticoagulants require cardiologist clearance before ibogaine treatment. Ibogaine may affect INR in warfarin patients through CYP2C9/2C19 interactions. Many clinics do not accept patients on anticoagulants without dedicated cardiology consultation. Individual risk-benefit assessment with a cardiologist is mandatory.

Block ibogaine metabolism, causing elevated plasma levels, prolonged duration, and increased cardiac exposure. Must be fully cleared before treatment. QTc monitoring is especially critical in patients with recent CYP2D6 inhibitor use.

Meaningfully increase ibogaine exposure. Require complete washout based on their own pharmacokinetic half-lives. Diphenhydramine (common sleep aid and allergy medication) is a frequently overlooked moderate CYP2D6 inhibitor.

Accelerate ibogaine metabolism, potentially reducing therapeutic effectiveness and causing an unexpectedly rapid shift to noribogaine pharmacology. May result in treatment appearing less effective.

Acute alcohol use within 24-48 hours of ibogaine is contraindicated. Alcohol competes for hepatic metabolism with ibogaine and elevates cardiac risk through QTc prolongation and electrolyte disruption. Chronic alcoholism creates additional challenges: alcohol withdrawal syndrome (which can be medically dangerous independent of ibogaine) may be triggered, liver function may be impaired affecting ibogaine metabolism, and nutritional deficiencies — especially thiamine (B1) — must be corrected. Most clinics require 7-10 days of abstinence minimum; patients with alcohol use disorder may require medically supervised detox first.

Stimulants are among the most dangerous combinations with ibogaine. They increase heart rate, raise blood pressure, and independently prolong the QT interval — all of which compound ibogaine's cardiac effects to potentially fatal levels. Cocaine also causes coronary vasospasm. Clinics detect stimulant use on urine toxicology and will not proceed with active stimulant presence. Beyond acute treatment, active cocaine dependence affecting cardiac structure (cocaine cardiomyopathy) requires cardiology evaluation before ibogaine is considered at all.

MDMA massively increases serotonin release and blocks reuptake — a direct serotonin syndrome combination with ibogaine. MDMA also prolongs the QT interval and causes hyperthermia. Complete clearance (minimum 2 weeks, confirmed by tox screen) is required before ibogaine treatment. History of heavy MDMA use should prompt cardiac screening for structural changes, particularly for patients with concurrent heat exposure history.

Acute opioid intoxication at the time of ibogaine is contraindicated — the combination of CNS depressants and ibogaine's stimulant cardiac effects creates unpredictable hemodynamic instability. Chronic opioid users without formal medication-assisted treatment should be assessed for physical dependence level; sudden opioid cessation can trigger withdrawal that ibogaine helps resolve, but timing and monitoring are critical. Fentanyl is particularly complex due to its extreme potency and tissue accumulation — specialized protocols apply.

Cannabis does not have a well-documented pharmacokinetic danger with ibogaine. However, THC can increase anxiety and psychotic symptoms — effects that ibogaine amplifies. Patients with cannabis-induced anxiety or psychosis-sensitive conditions should abstain for at least 1 week before treatment. High-dose CBD has some CYP enzyme inhibition potential but is generally low-risk. Some clinics allow cannabis use during the integration period post-treatment; others discourage any substance use during the neuroplasticity window. Disclose cannabis use and frequency honestly.

St. John's Wort creates double jeopardy with ibogaine. It inhibits serotonin reuptake (like an SSRI), creating serotonin syndrome risk. Simultaneously, it strongly induces CYP2D6 and CYP3A4 enzymes — the enzymes that metabolize ibogaine — potentially causing unpredictable changes in ibogaine plasma levels and duration. Discontinue at least 2-3 weeks before ibogaine. Inform your clinic, as some require longer washout periods.

5-HTP is a direct serotonin precursor. Taking it with ibogaine or noribogaine — which both block serotonin reuptake — floods the serotonergic system with additional substrate. This is a well-recognized serotonin syndrome combination in the pharmacology literature. Discontinue at least 1-2 weeks before ibogaine. Also avoid in the 2-4 week post-treatment window while noribogaine remains active.

Kratom contains mitragynine and 7-hydroxymitragynine, which act as partial mu-opioid receptor agonists — the same receptors ibogaine targets for its anti-addictive effect. Kratom use can blunt ibogaine's therapeutic mechanism, similarly to (but less severely than) buprenorphine. Kratom also affects serotonin systems. Current medical consensus recommends discontinuing kratom at least 7-10 days before ibogaine treatment.

Kava has significant GABA-A modulating activity and may interact with ibogaine's effects on GABAergic tone. Additionally, kava carries hepatotoxicity risk — combining it with ibogaine, which undergoes extensive hepatic metabolism, may stress liver function. Discontinue at least 7 days before treatment and inform the clinical team.

Valerian modulates GABA-A receptors similarly to benzodiazepines but far more mildly. Low-dose use is unlikely to be clinically significant. High-dose valerian (above 900mg/day) used as a sleep aid should be disclosed and tapered in the week before treatment. Valerian is commonly recommended for sleep in the post-treatment integration period at standard doses.

Melatonin has no significant pharmacokinetic interaction with ibogaine during treatment. It is actually recommended for post-treatment sleep management beginning 48 hours after the acute phase. Standard doses (0.5-5mg) are considered safe throughout the integration period.